Chiesi Farmaceutici SpA - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chiesi Farmaceutici SpA - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Chiesi Farmaceutici SpA - Product Pipeline Review - 2015', provides an overview of the Chiesi Farmaceutici SpA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chiesi Farmaceutici SpA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Chiesi Farmaceutici SpA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Chiesi Farmaceutici SpA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Chiesi Farmaceutici SpA's pipeline products

Reason to Buy

- Evaluate Chiesi Farmaceutici SpA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Chiesi Farmaceutici SpA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Chiesi Farmaceutici SpA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Chiesi Farmaceutici SpA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chiesi Farmaceutici SpA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Chiesi Farmaceutici SpA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Chiesi Farmaceutici SpA Snapshot 6
Chiesi Farmaceutici SpA Overview 6
Key Information 6
Key Facts 6
Chiesi Farmaceutici SpA - Research and Development Overview 7
Key Therapeutic Areas 7
Chiesi Farmaceutici SpA - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Chiesi Farmaceutici SpA - Pipeline Products Glance 17
Chiesi Farmaceutici SpA - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Chiesi Farmaceutici SpA - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Chiesi Farmaceutici SpA - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Chiesi Farmaceutici SpA - Drug Profiles 22
(beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Lamazym 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
meropenem 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ACE-527 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CHF-6001 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
glycopyrrolate 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CHF-5633 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ACE-920 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CPD-15 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug for Cystic Fibrosis 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Galaczym 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Agonize Glucocorticoid Receptor for Asthma and COPD 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Bronchopulmonary Dysplasia 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Inhibit Neutrophil Elastases for Respiratory Diseases 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit P38 for Respiratory Diseases 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ZA-011 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Chiesi Farmaceutici SpA - Pipeline Analysis 45
Chiesi Farmaceutici SpA - Pipeline Products by Target 45
Chiesi Farmaceutici SpA - Pipeline Products by Route of Administration 46
Chiesi Farmaceutici SpA - Pipeline Products by Molecule Type 47
Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action 48
Chiesi Farmaceutici SpA - Recent Pipeline Updates 49
Chiesi Farmaceutici SpA - Dormant Projects 50
Chiesi Farmaceutici SpA - Discontinued Pipeline Products 51
Discontinued Pipeline Product Profiles 51
carmoterol 51
indantadol 51
Chiesi Farmaceutici SpA - Company Statement 52
Chiesi Farmaceutici SpA - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Chiesi Farmaceutici SpA, Key Information 6
Chiesi Farmaceutici SpA, Key Facts 6
Chiesi Farmaceutici SpA - Pipeline by Indication, 2015 8
Chiesi Farmaceutici SpA - Pipeline by Stage of Development, 2015 10
Chiesi Farmaceutici SpA - Monotherapy Products in Pipeline, 2015 11
Chiesi Farmaceutici SpA - Combination Treatment Modalities in Pipeline, 2015 12
Chiesi Farmaceutici SpA - Partnered Products in Pipeline, 2015 13
Chiesi Farmaceutici SpA - Partnered Products/ Combination Treatment Modalities, 2015 14
Chiesi Farmaceutici SpA - Out-Licensed Products in Pipeline, 2015 15
Chiesi Farmaceutici SpA - Out-Licensed Products/ Combination Treatment Modalities, 2015 16
Chiesi Farmaceutici SpA - Phase III, 2015 17
Chiesi Farmaceutici SpA - Phase II, 2015 18
Chiesi Farmaceutici SpA - Phase I, 2015 19
Chiesi Farmaceutici SpA - Preclinical, 2015 20
Chiesi Farmaceutici SpA - Discovery, 2015 21
Chiesi Farmaceutici SpA - Pipeline by Target, 2015 45
Chiesi Farmaceutici SpA - Pipeline by Route of Administration, 2015 46
Chiesi Farmaceutici SpA - Pipeline by Molecule Type, 2015 47
Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action, 2015 48
Chiesi Farmaceutici SpA - Recent Pipeline Updates, 2015 49
Chiesi Farmaceutici SpA - Dormant Developmental Projects,2015 50
Chiesi Farmaceutici SpA - Discontinued Pipeline Products, 2015 51
Chiesi Farmaceutici SpA, Subsidiaries 53